Thrombotic thrombocytopenic purpura screening: Difference between revisions
No edit summary |
|||
| Line 2: | Line 2: | ||
{{Xyz}} | {{Xyz}} | ||
{{CMG}}; {{AE}} | {{CMG}}; {{AE}} {{S.G.}} | ||
==Overview== | ==Overview== | ||
Revision as of 20:54, 13 September 2018
|
Xyz Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Thrombotic thrombocytopenic purpura screening On the Web |
|
American Roentgen Ray Society Images of Thrombotic thrombocytopenic purpura screening |
|
Risk calculators and risk factors for Thrombotic thrombocytopenic purpura screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sogand Goudarzi, MD [2]
Overview
There is insufficient evidence to recommend routine screening for [disease/malignancy].
OR
According to the [guideline name], screening for [disease name] is not recommended.
OR
According to the [guideline name], screening for [disease name] by [test 1] is recommended every [duration] among patients with [condition 1], [condition 2], and [condition 3].
Screening
There is no insufficient evidence to recommend routine screening for TTP.[1]
First test to be screening for ADAMTS13 activity. ADAMTS13 activity < 10%, TTP diagnosis is confirmed.
In sever deficiency of ADAMTS13 second screening is detection of anti-ADAMTS13 IgG
Gene sequencing of DAMTS13 is a third test is used.
References
- ↑ Joly, Bérangère S.; Coppo, Paul; Veyradier, Agnès (2017). "Thrombotic thrombocytopenic purpura". Blood. 129 (21): 2836–2846. doi:10.1182/blood-2016-10-709857. ISSN 0006-4971.